AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Tenax Therapeutics Inc (NASDAQ:TENX)
12 USD
+0.130 1.095%Sponsored Reports
Loading...
| Previous Close (in USD) | 11.87 |
|---|---|
| Change | +0.130 1.095% |
| 52 W H/L (in USD) | 57.576/3.440 |
| EBITDA (in USD) | -10.594M |
| PE Ratio | -- |
| Volume | 2691091 |
| Diluted Eps TTM | -22.06 |
| Total Assets (in USD) | 11.685M |
|---|---|
| Total Liabilities (in USD) | 3.587M |
| Revenue TTM (in USD) | -- |
| Cash (in USD) | 9.792M |
| Market Cap (in USD) | 6.873 M |
| Revenue Per Share TTM | -- |
| Gross Profit TTM (in USD) | -- |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
Tenax Therapeutics Inc
Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.
101 Glen Lennox Drive, Chapel Hill, NC, United States, 27517
919 855 2100
Employees: 5
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Christopher T. Giordano | CEO, Pres & Director | 1975 |
| 2. | Mr. Eliot M. Lurier CPA | Interim Chief Financial Officer | 1958 |
| 3. | Dr. Stuart Rich M.D. | Chairman of Scientific Advisory Board, Chief Medical Officer & Director | 1950 |
| 4. | Ms. Nancy J. M. Hecox | Exec. VP of Legal Affairs, Gen. Counsel & Corp. Sec. | NA |
| 5. | Mr. Doug Randall | Exec. VP of Commercial & Bus. Operations | NA |
| 6. | Dr. Douglas Hay | Sr. VP of Regulatory Affairs | NA |
| 7. | Mr. Christopher T. Giordano | CEO, President & Director | 1975 |
| 8. | Dr. Stuart Rich M.D. | Chief Medical Officer & Director | 1950 |
| 9. | Mr. Lawrence R. Hoffman CPA, Esq. | Interim Chief Financial Officer | 1955 |
| 10. | Mr. Doug Randall | Executive Vice President of Commercial & Business Operations | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.330 0.758% | 43.45 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
0.000 0.000% | 43 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-7.360 1.604% | 462.17 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+2.010 0.331% | 612.07 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -11.048M | -32.474M | -9.851M | -8.394M | -6.813M |
| Minority Interest | - | - | - | - | - |
| Net Income | -11.043M | -32.73M | -9.871M | -8.394M | -6.734M |
| Selling General Administrative | 5.675M | 7.581M | 5.307M | 5.084M | 5.654M |
| Gross Profit | - | - | - | - | 0M |
| Reconciled Depreciation | 0.113M | 0.109M | 0.115M | 0.107M | 0.009M |
| Ebit | -11.053M | -32.728M | -9.868M | -8.555M | -6.893M |
| Ebitda | -10.93M | -32.364M | -9.735M | -8.448M | -6.884M |
| Depreciation And Amortization | 0.123M | 0.364M | 0.133M | 0.107M | 0.009M |
| Operating Income | -11.053M | -32.728M | -9.868M | -8.555M | -6.893M |
| Other Operating Expenses | 11.053M | 32.728M | 9.868M | 8.555M | 6.893M |
| Interest Expense | 0.004M | 0.001M | 0.002M | 0M | 0M |
| Tax Provision | - | - | - | - | - |
| Interest Income | - | - | - | - | - |
| Net Interest Income | -0.004M | -0.001M | -0.002M | - | - |
| Income Tax Expense | -0.005M | 0.256M | 0.02M | -0.161M | -0.08M |
| Total Revenue | 0M | 0M | 0M | 0M | 0M |
| Total Operating Expenses | 11.053M | 32.728M | 9.868M | 8.555M | 6.893M |
| Cost Of Revenue | - | - | - | - | 0M |
| Total Other Income Expense Net | 0.005M | 0.254M | 0.017M | 0.161M | 0.08M |
| Net Income From Continuing Ops | -11.048M | -32.474M | -9.851M | -8.394M | -6.813M |
| Net Income Applicable To Common Shares | - | -32.474M | -9.851M | -8.394M | -14.144M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 11.685M | 3.405M | 5.992M | 6.869M | 6.365M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 1.891M | 0.346M | 0.105M | 0.083M | 0.781M |
| Total Liab | 3.587M | 1.912M | 1.748M | 2.243M | 2.593M |
| Total Stockholder Equity | 8.098M | 1.493M | 4.245M | 4.626M | 3.772M |
| Other Current Liab | 1.012M | 0.656M | 0.597M | 1.18M | 0.76M |
| Common Stock | 0M | 0.005M | 0.003M | 0.001M | 0.001M |
| Capital Stock | 0M | 0.005M | 0.003M | 0.001M | 0.001M |
| Retained Earnings | -297.253M | -289.542M | -278.494M | -246.02M | -236.168M |
| Good Will | - | - | - | - | - |
| Other Assets | - | - | 0.008M | 0.008M | 0.008M |
| Cash | 9.792M | 2.124M | 5.584M | 6.25M | 4.906M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 3.587M | 1.848M | 1.564M | 2.119M | 2.532M |
| Current Deferred Revenue | 0M | - | - | - | - |
| Net Debt | -9.291M | -1.316M | -5.293M | -5.945M | -4.734M |
| Short Term Debt | 0.501M | 0.744M | 0.107M | 0.181M | 0.111M |
| Short Long Term Debt | 0.501M | 0.624M | - | 0.12M | - |
| Short Long Term Debt Total | 0.501M | 0.808M | 0.291M | 0.305M | 0.172M |
| Other Stockholder Equity | 305.351M | 291.03M | 282.736M | 250.644M | 239.94M |
| Property Plant Equipment | - | - | 0.295M | 0.065M | 0.007M |
| Total Current Assets | 11.684M | 3.208M | 5.689M | 6.796M | 6.181M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | - | - | 0M | 0.463M | 0.494M |
| Net Receivables | - | - | - | - | - |
| Long Term Debt | - | - | - | 0.124M | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | 2.073M | 0.448M | 0.86M | 0.758M | 1.661M |
| Accumulated Other Comprehensive Income | - | - | - | -0M | 0M |
| Non Currrent Assets Other | 0.001M | 0.01M | 0.008M | 0.008M | 0.008M |
| Non Current Assets Total | 0.001M | 0.196M | 0.303M | 0.073M | 0.184M |
| Capital Lease Obligations | 0M | 0.184M | 0.291M | 0.06M | 0.172M |
| Long Term Debt Total | - | - | - | 0.124M | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -0.002M | 0.458M | 0.024M | 0.002M | 7.362M |
| Total Cashflows From Investing Activities | - | 0.453M | 0.02M | -0.002M | 7.355M |
| Total Cash From Financing Activities | 8.555M | 9.737M | 10.597M | 0.097M | 8.907M |
| Net Income | -11.048M | -32.474M | -9.851M | -8.394M | -14.144M |
| Change In Cash | -3.46M | -0.666M | 1.344M | -7.461M | 10.763M |
| Begin Period Cash Flow | 5.584M | 6.25M | 4.906M | 12.367M | 1.605M |
| End Period Cash Flow | 2.124M | 5.584M | 6.25M | 4.906M | 12.367M |
| Total Cash From Operating Activities | -12.013M | -10.856M | -9.273M | -7.556M | -5.499M |
| Depreciation | 0.113M | 0.109M | 0.115M | 0.107M | 0.009M |
| Other Cashflows From Investing Activities | - | - | - | 0.002M | 7.362M |
| Dividends Paid | - | - | - | - | 7.331M |
| Change To Inventory | - | 0.545M | 0.536M | -0.883M | -0.729M |
| Sale Purchase Of Stock | - | - | 10.352M | 0.097M | 8.907M |
| Other Cashflows From Financing Activities | 8.19M | 0.545M | 1.938M | -0.075M | 15.922M |
| Capital Expenditures | 0.002M | 0.005M | 0.003M | 0.004M | 0.008M |
| Change In Working Capital | -1.445M | -0.61M | 0.102M | 0.46M | 0.607M |
| Other Non Cash Items | 0.367M | 22.119M | 0.361M | 0.271M | 7.431M |
| Free Cash Flow | -12.015M | -10.861M | -9.276M | -7.56M | -5.507M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Institutional Extnd Mkt Idx Tr | 2 years ago | 2326 |
| 2. | Fidelity Extended Market Index | 2 years ago | 1453 |
| 3. | NT Ext Equity Mkt Idx Fd - DC - NL - T2 | 2 years ago | 752 |
| 4. | Fidelity Nasdaq Composite Index | 2 years ago | 384 |
| 5. | NT US Market Cap Idx Fd - L | 2 years ago | 136 |
| 6. | NT Ext Equity Mkt Idx Fd - NL | 2 years ago | 12 |
| 7. | State St US Extended Mkt Indx NL Cl C | 2 years ago | 11 |
| 8. | NT Ext Equity Mkt Idx Fd - L | 2 years ago | 9 |
| 9. | Northern Trust Extended Eq Market Idx | 2 years ago | 9 |
| 10. | Northern Trust Wilshire 5000 | 2 years ago | 2 |
| 11. | SSgA U.S. Total Market Index Strategy | 2 years ago | 242 |
| 12. | NT US Market Cap Idx Fd - L | 2 years ago | 136 |
| 13. | Northern Trust Wilshire 5000 | 2 years ago | 136 |
| 14. | NT Ext Eq Mkt Indx Fd DC Lending Tier 5 | 2 years ago | 30 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Atlantic Trust Group, LLC | 2 years ago | 343 |
| 2. | Hanson Mcclain Inc | 2 years ago | 0 |
| 3. | Lido Advisors, LLC | 2 years ago | 0 |
| 4. | LPL Financial Corp | 2 years ago | 0 |
| 5. | Honkamp Krueger Financial Services Inc | 2 years ago | 0 |
| 6. | Virtu Financial LLC | 2 years ago | 0 |
| 7. | TWO SIGMA SECURITIES, LLC | 2 years ago | 0 |
| 8. | Citadel Advisors Llc | 2 years ago | 15033 |
| 9. | Honkamp Krueger Financial Services Inc | 2 years ago | 10002 |
| 10. | Lido Advisors, LLC | 2 years ago | 10000 |
| 11. | Tower Research Capital LLC | 2 years ago | 4653 |
| 12. | Morgan Stanley - Brokerage Accounts | 2 years ago | 675 |
| 13. | Wells Fargo & Co | 2 years ago | 160 |
| 14. | Banque Cantonale Vaudoise | 2 years ago | 50 |
| 15. | Hanson Mcclain Inc | 2 years ago | 3 |
| 16. | TUCKER ASSET MANAGEMENT LLC | 2 years ago | 2 |
| 17. | Verition Fund Managegment, LLC | 2 years ago | 0 |
| 18. | Millennium Management LLC | 2 years ago | 0 |
| 19. | HRT FINANCIAL LLC | 2 years ago | 0 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...